(Q34616904)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Natalie J Carter

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

355-376

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

Marine metabolites overcoming or circumventing multidrug resistance mediated by ATP-dependent transporters: a new hope for patient with tumors resistant to conventional chemotherapy

18 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11202860-000000000-00000

Diagnosis and management of epithelial ovarian cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11202860-000000000-00000

7505 ORAL Personalized therapy with trabectedin (Yondelis®) in advanced pre-treated sarcomas

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11202860-000000000-00000

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

12 December 2020

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.

1 reference

12 December 2020

Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin

1 reference

12 December 2020

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin

1 reference

12 December 2020

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

1 reference

12 December 2020

In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug

1 reference

12 December 2020

1 reference

12 December 2020

Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity

1 reference

12 December 2020

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

1 reference

12 December 2020

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

1 reference

12 December 2020

A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study

1 reference

12 December 2020

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma

1 reference

12 December 2020

Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft

1 reference

12 December 2020

Biomarkers in cancer staging, prognosis and treatment selection

1 reference

12 December 2020

In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects

1 reference

12 December 2020

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

1 reference

12 December 2020

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

1 reference

12 December 2020

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.

1 reference

12 December 2020

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat

1 reference

12 December 2020

Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex

1 reference

12 December 2020

Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma

1 reference

12 December 2020

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

1 reference

12 December 2020

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

1 reference

12 December 2020

Epidemiological aspects of soft tissue sarcomas (STS)--consequences for the design of clinical STS trials.

1 reference

12 December 2020

Ecteinascidin-743 inhibits activated but not constitutive transcription.

1 reference

12 December 2020

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

1 reference

12 December 2020

Soft-tissue sarcomas in adults

1 reference

12 December 2020

Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

1 reference

12 December 2020

Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

1 reference

12 December 2020

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

1 reference

12 December 2020

Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma

1 reference

12 December 2020

Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer

1 reference

12 December 2020

Role of homologous recombination in trabectedin-induced DNA damage

1 reference

12 December 2020

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

1 reference

12 December 2020

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

1 reference

12 December 2020

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

1 reference

12 December 2020

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

12 December 2020

Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs

1 reference

12 December 2020

Current management strategies for ovarian cancer

1 reference

12 December 2020

In vitro radiosensitisation by trabectedin in human cancer cell lines.

1 reference

12 December 2020

Trabectedin--a targeted chemotherapy?

1 reference

12 December 2020

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

1 reference

12 December 2020

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

12 December 2020

Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).

1 reference

12 December 2020

Survival from cancer of the ovary in England and Wales up to 2001

1 reference

12 December 2020

In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping.

1 reference

12 December 2020

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

1 reference

12 December 2020

ET-743: a novel agent with activity in soft-tissue sarcomas

1 reference

12 December 2020

Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin

1 reference

12 December 2020

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

1 reference

12 December 2020

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

12 December 2020

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

1 reference

12 December 2020

In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

1 reference

12 December 2020

Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

The combination of yondelis and cisplatin is synergistic against human tumor xenografts

1 reference

12 December 2020

Ovarian cancer. Clinical practice guidelines in oncology

1 reference

12 December 2020

Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma

1 reference

12 December 2020

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

12 December 2020

Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.

1 reference

12 December 2020

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

1 reference

12 December 2020

Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.

1 reference

12 December 2020

Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells

1 reference

12 December 2020